Target intelligence / Profile preview

Mucins and mucoproteins (MUC) (MUC)

Target
MUC
Molecular classification
Glycoprotein, Secretory protein, Membrane-bound protein
01

Overview

Mucins are a family of high-molecular-weight, heavily glycosylated proteins that serve as the primary structural components of mucus, a viscoelastic gel coating epithelial surfaces (Wikipedia, 2024). They are categorized into secreted (gel-forming) and membrane-bound types, playing essential roles in lubrication, hydration, and providing a physical and chemical barrier against pathogens and toxins (NIH, 2022). Structurally, mucins consist of a protein backbone rich in serine and threonine residues, which are extensively O-glycosylated to form a brush-like architecture (NIH, 2022). In respiratory diseases like cystic fibrosis and COPD, mucin hypersecretion and altered cross-linking lead to airway obstruction and chronic infection (StatPearls, 2023). In oncology, aberrant mucin expression and glycosylation (e.g., MUC1, MUC16) are hallmarks of epithelial cancers, contributing to tumor progression, metastasis, and drug resistance (PubMed, 2023). Therapeutic interventions include mucolytic agents that break down the mucin network to improve clearance and emerging targeted therapies that inhibit mucin production or secretion in cancer and inflammatory conditions (NIH, 2024). These proteins also serve as critical biomarkers for disease progression and treatment efficacy in both respiratory and oncological settings (Creative Biogene, 2024).

Other names
Mucins and other mucoproteins in mucus/viscous secretionsMucus glycoproteinsMucoproteinsMUC proteinsGel-forming mucinsMembrane-bound mucins
02

Mechanism of action

Reduction of disulfide bonds in mucin polymers, enzymatic degradation of extracellular DNA and actin in secretions, modulation of mucin gene expression and secretion, and antibody-mediated targeting of membrane-bound mucins in cancer.

03

Biological functions

LubricationPhysical barrierImmune defenseCell signalingCell adhesionHydration
04

Disease associations

Cystic fibrosisChronic obstructive pulmonary disease (COPD)AsthmaBronchitisCancerInflammatory bowel disease (IBD)Gastritis
05

Safety considerations

BronchospasmGastrointestinal irritationDisruption of the protective mucosal barrierPotential for increased infection risk if barrier is compromised
06

Interacting drugs

N-acetylcysteine

9 more in the full profile.

07

Biomarkers

MUC1 (CA15-3)MUC16 (CA125)MUC5ACMUC5BCA19-9

Beyond the preview

Go deeper on Mucins and mucoproteins (MUC) (MUC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mucins and mucoproteins (MUC) (MUC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call